Prostate cancer trial: targeted biopsy then immediate surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial is for men with a high probability of clinically significant prostate cancer. It uses a special prediction model to identify high-risk patients, then performs a targeted biopsy and immediate surgery, all in one streamlined process.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a clinical suspicion of prostate cancer (based on a rectal exam or PSA test).
- You need to have had both a total PSA blood test and a special MRI scan (mpMRI).
- Your total PSA level must be between 4 and 100 ng/mL.
- You must score at least 60% risk on an online prostate cancer prediction tool.
- You should be healthy enough to undergo a prostate biopsy and prostate removal surgery.
- You should not have a bleeding disorder or be taking blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This trial compares two ways of treating localized prostate cancer: H-FIRE versus laparoscopic prostate surgery. It may help find which approach works best for people with early-stage, non-spread prostate cancer.
This study checks whether a faster prostate MRI and image-matching (image-fusion) can better find suspicious spots so doctors can target a biopsy. If you have concerning prostate exam results or PSA blood test results, you may get an MRI and, if something looks suspicious, a biopsy using MRI images.
This trial tests whether a new imaging technique (PSMA-PET/MRI fused with ultrasound) helps surgeons perform more precise robotic prostate removal in men with prostate cancer that has started to spread outside the gland. It aims to improve cancer control and reduce side effects.
This study tests a new way to guide prostate biopsies using a special scan (PSMA PET/CT) that highlights suspicious areas. If you need a biopsy because of high PSA and abnormal MRI, this approach might help make the biopsy more accurate.
This trial tests whether adding a targeted biopsy to a standard sextant biopsy improves the detection of prostate cancer. It is for men aged 45 to 85 who have a suspicious spot on an MRI of their prostate and have not had a biopsy before.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.